FDA Approves Eli Lilly's Foundayo, a Once-Daily Oral GLP-1 Pill for Obesity With No Food or Water Restrictions
The FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist from Eli Lilly, for adults with obesity or overweight. It is the first new molecular entity approved under the National Priority Voucher program and the fastest NME approval since 2002.
4 min read3 sources